| Title： | Expert Consensus on Early Treatment of Critical Illness Guided by the Theory of Aldehyde Metabolism Disorder |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Diagnosis and Treatment |
| Countries and regions： | China |
| Guidelines users： | Emergency Department, Intensive Care Department, Respiratory and Critical Care Department, Cardiology Department, Cardiac Surgeons and Nurses, General Practitioners and Nurses |
| Evidence classification method： | Consensus meetings and expert votes |
| Development unit： | Emergency Medicine Branch of the Chinese Medical Association; Chest Pain Branch of the China Association for International Exchange and Promotion of Healthcare; Expert Group of the Multidisciplinary Joint Committee on Cardiopulmonary Resuscitation and Extracorporeal Life Support under the Guidance of Aldehyde Metabolism Disorder Theory for Early Treatment of Critical Illness, Shandong Medical Association |
| Registration time: | 2023-10-31 |
| Registration number： | PREPARE-2023CN810 |
| Purpose of the guideline: | Aldehyde metabolism disorders have been proven to play an undeniable role in various critically ill diseases, such as acute coronary syndrome, pulmonary hypertension, acute respiratory distress syndrome, sepsis, organ dysfunction, cardiac arrest, aortic dissection, and aneurysm. Aldehyde dehydrogenase 2 (ALDH2) is a key enzyme for detoxifying ethanol-derived acetaldehyde and endogenous lipid aldehydes such as 4-hydroxy-2-nonenal (4-HNE) or malondialdehyde. Carriers of the ALDH2 rs671 inactivation gene have an increased risk of many diseases compared to the general population, including cancer, neurodegeneration, and cardiovascular disease. We hope to apply the theory of aldehyde metabolism disorder based on existing evidence to guide early treatment of critically ill patients. |
Latest registration
